FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3215691731> ?p ?o ?g. }

• W3215691731 endingPage "1198" @default.
• W3215691731 startingPage "1177" @default.
• W3215691731 abstract "AD is a chronic relapsing disease characterized by pruritis and chronic inflammatory skin changes, (1) which affects approximately 10–30% of children and as much as 10% of adults worldwide.(2) This condition has a great significant impact on morbidity and presents an outstanding social economic burden.(3) AD is a multifactorial disease that develop by interaction between these factors in a positive feedback cycle. Treatment of AD interrupts the causal pathway. Management with conventional therapies has been a challenge, but a novel biological treatment called dupilumab was recently approved for the treatment of moderate-to-severe AD, but this drug only achieved 40% clear skin in combination with TCs.(4). JAK inhibitors are another new drug family that inhibit JAK-signaling pathways, which involve JAK1, JAK2, JAK3 and TYK2. JAK inhibitors have been approved to treat inflammatory diseases like rheumatoid arthritis, and high attention is currently being focused on the clinical development of JAK inhibitors for the treatment of AD. Which are a possible treatment for certain disease that are related to lymphocyte activation, such as psoriasis, alopecia areata, vitiligo and AD. JAK inhibitors are available in topical and oral forms, thereby allowing more administration routes depending on the severity of AD, which ranges from mild to severe. Since JAK inhibitors are a new treatment modality in dermatology, the efficacy of this new medicine and the safety thereof are still being debated. A systematic review and meta‐analysis were done for all randomized clinical trials that evaluated JAK inhibitors for Atopic dermatitis to investigate their pooled efficacy and safety compared to placebo. Results might be useful as a milestone to develop a more accurate view of this medication and provide direction for further research." @default.
• W3215691731 created "2021-12-06" @default.
• W3215691731 creator A5006188755 @default.
• W3215691731 creator A5035845754 @default.
• W3215691731 date "2021-10-31" @default.
• W3215691731 modified "2023-09-26" @default.
• W3215691731 title "JAK INHIBITORS AS A NEW MODALITY FOR TREATING ATOPIC DERMATITIS: A BETTER UNDERSTANDING OF ITS EFFICACY AND SAFETY" @default.
• W3215691731 doi "https://doi.org/10.21474/ijar01/13666" @default.
• W3215691731 hasPublicationYear "2021" @default.
• W3215691731 type Work @default.
• W3215691731 sameAs 3215691731 @default.
• W3215691731 citedByCount "0" @default.
• W3215691731 crossrefType "journal-article" @default.
• W3215691731 hasAuthorship W3215691731A5006188755 @default.
• W3215691731 hasAuthorship W3215691731A5035845754 @default.
• W3215691731 hasBestOaLocation W32156917311 @default.
• W3215691731 hasConcept C112392421 @default.
• W3215691731 hasConcept C126322002 @default.
• W3215691731 hasConcept C16005928 @default.
• W3215691731 hasConcept C203014093 @default.
• W3215691731 hasConcept C2776112149 @default.
• W3215691731 hasConcept C2777524370 @default.
• W3215691731 hasConcept C2777575956 @default.
• W3215691731 hasConcept C2778329239 @default.
• W3215691731 hasConcept C2778690821 @default.
• W3215691731 hasConcept C2779134260 @default.
• W3215691731 hasConcept C2779824493 @default.
• W3215691731 hasConcept C2779980618 @default.
• W3215691731 hasConcept C2780007613 @default.
• W3215691731 hasConcept C2780076729 @default.
• W3215691731 hasConcept C2780564577 @default.
• W3215691731 hasConcept C535046627 @default.
• W3215691731 hasConcept C71924100 @default.
• W3215691731 hasConceptScore W3215691731C112392421 @default.
• W3215691731 hasConceptScore W3215691731C126322002 @default.
• W3215691731 hasConceptScore W3215691731C16005928 @default.
• W3215691731 hasConceptScore W3215691731C203014093 @default.
• W3215691731 hasConceptScore W3215691731C2776112149 @default.
• W3215691731 hasConceptScore W3215691731C2777524370 @default.
• W3215691731 hasConceptScore W3215691731C2777575956 @default.
• W3215691731 hasConceptScore W3215691731C2778329239 @default.
• W3215691731 hasConceptScore W3215691731C2778690821 @default.
• W3215691731 hasConceptScore W3215691731C2779134260 @default.
• W3215691731 hasConceptScore W3215691731C2779824493 @default.
• W3215691731 hasConceptScore W3215691731C2779980618 @default.
• W3215691731 hasConceptScore W3215691731C2780007613 @default.
• W3215691731 hasConceptScore W3215691731C2780076729 @default.
• W3215691731 hasConceptScore W3215691731C2780564577 @default.
• W3215691731 hasConceptScore W3215691731C535046627 @default.
• W3215691731 hasConceptScore W3215691731C71924100 @default.
• W3215691731 hasIssue "10" @default.
• W3215691731 hasLocation W32156917311 @default.
• W3215691731 hasLocation W32156917312 @default.
• W3215691731 hasOpenAccess W3215691731 @default.
• W3215691731 hasPrimaryLocation W32156917311 @default.
• W3215691731 hasRelatedWork W11245813 @default.
• W3215691731 hasRelatedWork W11412807 @default.
• W3215691731 hasRelatedWork W12437156 @default.
• W3215691731 hasRelatedWork W1386413 @default.
• W3215691731 hasRelatedWork W16045063 @default.
• W3215691731 hasRelatedWork W22282136 @default.
• W3215691731 hasRelatedWork W2406414 @default.
• W3215691731 hasRelatedWork W5016363 @default.
• W3215691731 hasRelatedWork W5893972 @default.
• W3215691731 hasRelatedWork W14566330 @default.
• W3215691731 hasVolume "9" @default.
• W3215691731 isParatext "false" @default.
• W3215691731 isRetracted "false" @default.
• W3215691731 magId "3215691731" @default.
• W3215691731 workType "article" @default.